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Objective: To evaluate the efﬁcacy of the World Health Organization Fracture Risk Assessment Tool,
excluding bone mineral density (pre-BMD FRAX), in identifying Taiwanese postmenopausal women
needing dual-energy X-ray absorptiometry (DXA) examination for further treatment.
Materials and methods: The pre-BMD FRAX score was calculated for 231 postmenopausal women who
participated in public health education workshops in the local Keelung community, Taiwan. DXA scan-
ning and vertebral fracture assessment (VFA) were arranged for women classiﬁed as intermediate or high
risk for fracture using the pre-BMD FRAX fracture probability.
Results: Pre-BMD FRAX classiﬁed 26 women as intermediate risk and 37 as having high risk for fracture.
Subsequent DXA scans for these 63 women showed that 36 were osteoporotic, 19 were osteopenic, and
eight had normal bone density. Concurrent VFA revealed 25 spine factures in which 14 were osteoporotic,
seven were osteopenic, and four had normal bone density. The efﬁcacy of the pre-BMD FRAX score to
identify those patients with low bone mass by DXA was 87.3% (55/63). When VFA was combined with
BMD to identify those patients with high risk (osteopenia, osteoporosis, or spinal fracture), the efﬁcacy of
the pre-BMD score increased to 93.7% (59/63). According to the National Osteoporosis Foundation, the
overall concordance between pre-BMD FRAX and BMD, expressed through the kappa index, was 0.967.
Compared with the evaluation when BMD was used alone, there was a signiﬁcant increase in efﬁcacy in
identifying women who need treatment using BMD plus VFA or FRAX plus BMD. Furthermore, the
highest efﬁcacy was achieved when FRAX with BMD and VFA was used.
Conclusion: The pre-BMD FRAX score not only efﬁciently predicts postmenopausal patients who are
potentially at risk and might require treatment but also reduces unnecessary DXA use. Concurrent VFA
during DXA use increases spine fracture detection. This improvement in diagnostic efﬁcacy allows cli-
nicians to provide the most appropriate therapeutic recommendation.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Osteoporosis is deﬁned as a skeletal disorder characterized by
compromised bone strength, predisposing a person to an increased
risk of fracture [1]. Most cases of osteoporosis occur ins and Gynecology, Keelung
Keelung, Taiwan.
).
bstetrics & Gynecology. Publishedpostmenopausal women due to estrogen deﬁciency. Because
osteoporotic fractures in the spine and hip are associated with
substantially high morbidity and mortality, osteoporosis has
become a serious health threat for elderly women. Thus, it is
important to identify postmenopausal women who have low bone
mass and high fracture risk to provide preventive and pharmaco-
logic therapy.
Bone mineral density (BMD) is the most common measurement
used to evaluate bone strength. Dual-energy X-ray absorptiometryby Elsevier Taiwan LLC. All rights reserved.
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(WHO) as a technique of reference for assessing BMD in post-
menopausal women [2]. The most pivotal treatment guidelines, for
example, the National Osteoporosis Foundation (NOF) treatment
guideline [3], or studies also utilized the DXA T-score classiﬁcation
and a clinical history of vertebral or hip fractures to deﬁne the entry
criteria. The North American Menopause Society recommends that
BMD should be used in women aged 65 years or older and post-
menopausal women with medical causes of bone loss, additional
risk factors, or a fragility fracture [4]. However, it has been reported
that a larger population burden of fracture occurred in people with
osteopenia compared to thosewith osteoporosis [5]. From a health-
care perspective, fracture prevention should not depend only on
DXA testing.
Besides estrogen deﬁciency, there are many risk factors associ-
ated with osteoporotic fractures in postmenopausal women [4,6].
The WHO has developed a registered web-based clinical scale
assessing Fracture Risk Assessment Tool (FRAX) that integrates an
individual's risk factors and reports the 10-year probability of hip or
other major osteoporotic fracture [7,8]. FRAX can be calculatedwith
or without hip BMD and has provided both intervention thresholds
for treating osteoporosis and assessment thresholds for the use of
DXA.
It has been reported that up to half of all vertebral fractures are
not diagnosed [9]. It is well established that the existence of a
previous vertebral fracture increases the risk of subsequent frac-
tures, regardless of BMD. Greenspan et al [10] reported that in long-
term care residents, FRAX, based on femoral neck bone density
alone, identiﬁed 81% of participants for treatment but missed
almost 10% of women with silent vertebral fractures that might
beneﬁt from treatment. Thus, the identiﬁcation of a vertebral
fracture signiﬁcantly alters treatment decisions and considerations.
The aim of this studywas to assess the efﬁcacy of pre-BMD FRAX
scores in identifying postmenopausal women who need DXA
measurement for further treatment. In addition, this study also
evaluated the use of concurrent vertebral fracture assessment (VFA)
during DXA to improve osteoporosis risk detection.
Materials and methods
Study design
From January 2012 to June 2013, public health education
workshops and clinical services were held in the local community
of Keelung. A total of 231 postmenopausal womenwere enrolled in
the WHO pre-BMD FRAX evaluation. The enrollment criteria for
DXA and VFA examination were patients with intermediate FRAX
fracture risk (10e20% probability for major osteoporotic fracture or
1.5e3% for hip fracture) and high risk (S20% probability for major
osteoporotic fracture or S3% for hip fracture). The study was
approved by the Chang Gung Memorial Hospital Ethical Medicine
Committee.
FRAX score
FRAX scores were calculated with an online tool using the
Taiwan algorithm [7]. In brief, completion of 12 ﬁelds were
required, which included age (years); sex (male or female); height
(cm); weight (kg); history of previous fracture (deﬁned as a fracture
in adult life occurring spontaneously, or arising from traumawhich,
in a healthy individual, would not have resulted in a fracture);
history of parental hip fracture; current smoking; glucocorticoids
exposure (deﬁned as current exposure or previous oral glucocor-
ticoid exposure for >3 months, with a dose of 5 mg prednisolone
daily or more); diagnosis of rheumatoid arthritis; secondaryosteoporosis [including type I (insulin-dependent) diabetes,
osteogenesis imperfecta in adults, untreated long-standing hyper-
thyroidism, hypogonadism or premature menopause (<45 years),
chronic malnutrition or malabsorption, and chronic liver disease];
daily alcohol intake of more than three units; and femoral neck DXA
score (in g/cm2 or T score based on the National Health and
Nutrition Examination Survey III female reference data).
The FRAX scores were calculated ﬁrst using clinical factors alone
and were then reassessed with the inclusion of BMD (g/cm2) of
femoral neck.
BMD measurement and VFA
BMD of the hip (total hip, femoral neck) and posterioreanterior
spine (L1eL4) were measured by DXA scanning (GE-Lunar, iDAX,
Madison, WI, USA) installed at Keelung Chang Gung Memorial
Hospital. WHO guidelines were used to deﬁne BMD: a T score of
S1 denotes normal bone; a T score between1 and2.5 denotes
osteopenia, and a T score of &2.5 denotes osteoporosis. After
BMD measurement, the presence of vertebral fractures in the
thoracic or lumbar spine was determined by VFA with DXA scan-
ning simultaneously. VFA assesses T3eL4 vertebral fractures and
classiﬁes them according to Genant's criteria of mild, moderate, and
severe vertebral fractures [11].
Statistical analysis
The levels of agreements between BMD and FRAX þ BMD, BMD
and BMD þ VFA, and BMD and FRAX þ BMD þ VFA were assessed
using kappa statistic and Fisher exact test. Positive predictive value
(PPV) and negative predictive value (NPV) of NOF treatment
guideline [3] for pre-BMD FRAX, BMD, FRAX, BMD with VFA, and
FRAX with VFA were also calculated.
Results
A total of 63 patients (aged 48e81, mean age 66.2 years), who
were identiﬁed from pre-BMD FRAX, were enrolled. According to
the pre-BMD FRAX scores, 26 patients were classiﬁed as interme-
diate risk and 37 were classiﬁed as high risk for fracture. Clinical
risk factors evaluated by FRAX are shown in Table 1.
BMD and VFA of DXA scans were performed and evaluated by a
radiology specialist (Dr YC Lin). Results of DXA examination
(n ¼ 63) showed that 36 (57%) were osteoporotic, 19 (30.2%) were
osteopenic, and eight (12.7%) were normal for bone density. VFA
evaluation (n ¼ 63) showed that 25 patients had spine fracture
(Table 1). Of the 25 patients with spinal fractures, 14 were previ-
ously deemed to be osteoporotic, seven were osteopenic, and four
were identiﬁed from the eight patients with normal bone density
by DXA. From the results of the BMD alone, the efﬁcacy of the pre-
BMD FRAX score to identify the patients with low bone mass
[osteoporosis (n ¼ 36) or osteopenia (n ¼ 19)] by DXA was 87.3%
(55/63). Furthermore, when both BMD and VFA were used, the
efﬁcacy of the pre-BMD FRAX score increased to 93.7% (59/63) in
identifying high-risk patients (osteopenia, osteoporosis, or spinal
fracture).
According to the NOF treatment guideline [3], treatment is
recommended for patients with the following conditions: hip or
vertebral (clinical or asymptomatic) fractures, T scores of 2.5 or
less at the femoral neck, total hip, or lumbar spine by DXA, post-
menopausal women andmen aged 50 and older with osteopenia (T
score between 1.0 and 2.5) at the femoral neck, total hip, or
lumbar spine by DXA, and a 10-year hip fracture probability of 3% or
more or a 10-yearmajor osteoporosis-related fracture probability of
20% or more based on the WHO absolute fracture risk model
Table 1
Description of clinical predictors used in the WHO Fracture Risk Assessment Tool
(FRAX).
Clinical data/predictor Postmenopausal
women (N ¼ 63)
Pre-BMD FRAX score
(N ¼ 63)
N (%) unless
otherwise
noted
High risk
(N ¼ 37)
Intermediate
risk (N ¼ 26)
Age (y)
<65 27 (42.9) 4 23
65e75 25 (39.7) 22 3
>75 11 (17.5) 11 0
Body weight (kg) 55.7 ± 10.2 53.9 ± 10.2 58.3 ± 11.0
Body height (cm) 152.7 ± 5.9 151.0 ± 5.48 155.0 ± 5.74
History of fracture 7 (11.1) 5 (13.5%) 2 (7.7%)
Parental history of fracture 2 (3.2) 1 (2.7%) 1 (3.8%)
Current smoking 4 (6.3) 1 (2.7%) 3 (11.5%)
Three or more alcoholic
beverages/d
1 (1.6) 0 (0%) 1 (3.8%)
Rheumatoid arthritis 0 (0) 0 (0%) 0 (0%)
Glucocorticoid use 1 (1.6) 0 (0%) 1 (3.8%)
Secondary osteoporosis 23 (36.5) 15 (40.5%) 8 (30.8%)
DXA
T score  2.5a 36 25 11
2.5  T score  1 19 10 9
1  T score 8 2 6
Spine fracture by VFA 25 21 4
BMD ¼ bone mineral density; DXA ¼ dual-energy X-ray absorptiometry; FRAX ¼
Fracture Risk Assessment Tool; VFA ¼ vertebral fracture assessment; WHO ¼World
Health Organization.
a T score is bone mineral density in the hip and lumbar spine by DXA.
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FRAX scores showed a strong consensus with that from BMD
examination [kappa ¼ 0.967, 95% conﬁdence interval (CI)
0.904e1.031]. The PPV of treatment assignment by the FRAX score
was 97.3% in predicting treatment assignment by BMD results.
Alternatively, the NPV was 100% (Table 2).
In Table 3, in addition to PPV and NPV, use of BMD to identify
patients who need treatment showed fair concordancewith the use
of FRAX with BMD (kappa ¼ 0.7656, 95% CI 0.6064e0.9247), use of
BMD combined with VFA (kappa ¼ 0.6244, 95% CI 0.4375e0.8113),
and use of FRAX with BMD and VFA (kappa ¼ 0.5149, 95% CI
0.3189e0.7108). However, the efﬁcacy of these methods in
detecting osteoporosis was very different. Based on the afore-
mentioned treatment guideline, there was a 57.1% (36/63) efﬁcacy
in identifying high-risk patients needing treatment when only
BMD was used, 68.3% (43/63) when FRAX (including femoral neck
BMD) was used, and 74.6% (47/63) when BMD combined with VFA
was used. Furthermore, the efﬁcacy of identifying high-risk pa-
tients needing treatment was 79.4% (50/63) when FRAX with VFA
was used. These results also expose that if these patients only un-
derwent bone density criterion evaluation, 11 (7 osteopenic and 4
normal, assessed by BMD) of 25 patients (44%) with spine fractures
would go undetected.Table 2
Agreement between pre-BMD FRAX scores and BMD study in treatment
recommendation.
BMD, n Total
Treatment Reassurance
Pre-BMD FRAX
score, n
Treatment 36 1 37 PPV ¼ 97.3%
Reassurance 0 26 26 NPV ¼ 100%
Total 36 27 63
Kappa value ¼ 0.967, standard error of kappa ¼ 0.032 (95% CI: 0.904e1.031).
BMD ¼ bone mineral density; FRAX ¼ Fracture Risk Assessment Tool;
NPV ¼ negative predictive value; PPV ¼ positive predictive value.Discussion
The application of DXA is limited because it is nonportable,
expensive, and time consuming. A number of clinical risk factors
that provide information on fracture risk over that given by DXA
were reported [12]. To increase the cost effectiveness of DXA, the
clinical criteria of the FRAX score alone may also be useful in pre-
dicting patients who need DXA scans. This study demonstrated that
the pre-BMD FRAX score is highly correlated with the incidence of
osteoporotic patients as detected by DXA and as such may be
considered as an alternative screening strategy to identify eligible
patients in the community without DXA equipment. Although such
efﬁcacy is encouraging, several factors regarding these results still
warrant further examination.
In this study, the efﬁcacy of the pre-BMD FRAX score to identify
those patients with low bone mass through DXA use was 87.3%,
which increased to 93.7% after assessment with BMD combined
with VFA. These results conﬁrm that the use of pre-BMD FRAX to
identify intermediate and high-risk patients can reduce unnec-
essary DXA scanning. Moreover, it can be used as assessment
thresholds [8] to decide if DXA is needed. BMD alone is not optimal
for detection in individuals with high risk of fracture [13e15].
Several reports have revealed that the evaluation of clinical risk
factors that partially or totally contribute to fracture risk, inde-
pendent of BMD, have improved fracture prediction [16e20]. In this
study, only 57.1% of these women were found to need treatment
when DXA was used alone. However, when both FRAX and DXA
were used, the percentage of women identiﬁed to need treatment
increased to 68.3%. Furthermore, the PPV of treatment assignment
by the pre-BMD FRAX score was 97.3% and the NPV was 100%.
Because the strength of agreement between pre-BMD FRAX and
BMD is encouraging (kappa ¼ 0.967, 95% CI 0.904e1.031), we
conﬁrmed that the pre-BMD FRAX score is a suitable method to
identify not only those patients who need DXA evaluation but also
those who require therapy. Similar results have been reported in
patients with inﬂammatory bowel disease, in which the clinical
FRAX score alone, compared with the FRAX score that included
BMD, had a sensitivity of 100% and an NPV of 100% in identifying
those patients needing DXA measurement or preventive treatment
[21]. However, there were also some limitations in this study. In
addition to a small number of enrolled patients, no DXA data for
patients with low risk of FRAX score were available. Thus, the true
accuracy of the pre-BMD FRAX score could not be determined.
Vertebral fracture is the hallmark of osteoporosis. The incidence
of vertebral fracture is estimated to be approximately 10e15%
among women aged 50e59 years and increased to 50% for women
aged 80 years or more [22]. Radiologic imaging is required for the
detection of vertebral fractures but only approximately one third of
vertebral fractures are clinically apparent [23]. The speciﬁc criteria
to be used to select patients for spine imaging are still controversial.
In this study, VFA and BMD were performed concurrently during
DXA use. The efﬁcacy of the pre-BMD FRAX score to identify pa-
tients with high risk increases from 87.3% (with BMD only) to 93.7%
(BMD combined with VFA). The efﬁcacy of the pre-BMD FRAX score
also increases from 68.3% (FRAX including BMD) to 79.4% (FRAX
and VFA) when identifying patients needing treatment. If these
patients were evaluated only using BMD, 11 (7 osteopenic and 4
normal during BMD) of 25 patients (44%) with spinal fractures
would have been missed. Similar results were also reported by El
Maghraoui et al [24], in which 16% of the women with osteopenia
and 8.5% of the women with normal BMD who may have not been
identiﬁed as being at greater fracture risk were found to have un-
appreciated evident spinal fracture. The calculated kappa value and
PPV between BMD and FRAX þ BMD þ VFA were lower than the
results from other analyses. Therefore, it further conﬁrms that the
Table 3
Kappa index value between BMD and FRAX with BMD, BMD combined with VFA, or FRAX with BMD and VFA.
BMD, n ¼ 63
NOFa Treatment Reassurance Total Kappa value (standard error, 95% CI) PPV (%) NPV (%) Fisher exact test
FRAX þ BMD T 36 7 43 0.77 (0.08, 0.61e0.92) 83.7 100 6.584  1011
R 0 20 20
BMD þ VFA T 36 11 47 0.62 (0.10, 0.44e0.81) 76.6 100 3.56  108
R 0 16 16
FRAX þ BMD þ VFA T 36 14 50 0.51 (0.10, 0.32e0.71) 72.0 100 1.92  106
R 0 13 13
BMD ¼ bone mineral density; FRAX ¼ Fracture Risk Assessment Tool; NOF ¼ National Osteoporosis Foundation; NPV ¼ negative predictive value; PPV ¼ positive predictive
value; VFA ¼ vertebral fracture assessment.
a 2008 National Osteoporosis Foundation guidelines.
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risk factors and VFA, in addition to BMD. Moreover, this study also
demonstrates that concurrent use of VFA during DXA is a creditable
method to diagnose spine fractures in postmenopausal women.
In conclusion, pre-BMD FRAX can efﬁciently predict those pa-
tients needing treatment to reduce unnecessary DXA. Therefore,
pre-BMD FRAX may be applied in the community as well as in
general outpatient clinics. Furthermore, the addition of VFA during
DXAmeasurement can increase the diagnostic accuracy of vertebral
fracture detection and provide the most appropriate therapeutic
recommendation.
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